Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of lymphotoxin in treatment of medicine for increasing chemoradiotherapeutic sensitivity

A technology of lymphotoxin and chemotherapeutic drugs, applied in the application field of lymphotoxin in the preparation of drugs that increase the sensitivity of chemotherapeutic drugs, can solve the problems of large toxic and side effects, poor tolerance of patients, etc., and achieve the goal of improving the quality of life and reducing toxic and side effects Effect

Active Publication Date: 2014-11-26
上海复旦张江生物医药股份有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The purpose of the present invention is to provide a use of lymphotoxin, which is used as a sensitizer for tumor chemotherapy, so as to solve the shortcomings of current chemotherapy, such as large toxic side effects and poor patient tolerance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of lymphotoxin in treatment of medicine for increasing chemoradiotherapeutic sensitivity
  • Use of lymphotoxin in treatment of medicine for increasing chemoradiotherapeutic sensitivity
  • Use of lymphotoxin in treatment of medicine for increasing chemoradiotherapeutic sensitivity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0247] Embodiment 1.rhLT chemosensitization effect on BGC-823 (stomach cancer) cells

[0248] The experimental results are shown in Table 1. Carboplatin (CBDCA), cisplatin (CDDP), oxaliplatin (L-OHP), and doxorubicin (ADM) all showed synergistic effects in the three dose groups; Synergistic effect; mitomycin (MMC) only showed synergistic effect in the high-dose group; other drug groups showed additive or sub-additive effects.

[0249] Table 1 Chemosensitization effect of rhLT on BGC-823 (stomach cancer) cells

[0250] BGC-

[0251] (SFa)(SFb)

[0252] BGC-

[0253] BGC-

[0254] BGC-

[0255] Combined

[0256] BGC-

Embodiment 2

[0257] Example 2.rhLT Chemosensitization of NCI-H157 (non-small cell lung adenocarcinoma) cells

[0258] The experimental results are shown in Figure 1 and Table 2. Carboplatin (CBDCA), cisplatin (CDDP), and oxaliplatin (L-OHP) showed synergistic effects in the three dose groups; adriamycin (ADM) showed synergistic effects in the high-dose group and middle-dose group; other Drug groups have additive or sub-additive effects.

[0259] Table 2. Chemosensitizing effect of rhLT on NCI-H157 (non-small cell lung adenocarcinoma) cells

[0260] NCI-

[0261] NCI-

[0262] 0.1ug / ml

[0263] NCI-

[0264] NCI-

[0265] NCI-

[0266] LT(SFb)

Embodiment 3

[0267] Embodiment 3.rhLT is to the chemotherapy sensitization effect of SW480 (colon cancer) cell

[0268] The experimental results are shown in Table 3. Carboplatin (CBDCA) and cisplatin (CDDP) showed synergistic effect in the three dose groups; oxaliplatin (L-OHP) high-dose group and middle-dose group showed synergistic effect; group and low-dose group showed synergistic effect; other drug groups showed additive effect.

[0269] Table 3. Chemosensitizing effect of rhLT on SW480 (colon cancer) cells

[0270]

[0271]

[0272]

[0273]

[0274]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention concentrates on the protein engineering and the pharmacy domain, that is, the application of the lymphotoxin in the domanial of tumor therapy. It concerned with the purpose of one kind of lymphotoxin, as the sensitization agents of chemotherapy that it cures the epidermis source tumour. There is distinct cruative effect generated by applying lymphotoxin with chemotheraphy together, with platinum medicament especially. The advantages are: the application of the lymphotoxin with chemotheraphy improving the cruative effect or declines the chemotheraphy medicine dosage with permission of cruative effect gurantee, which it can reduces the nagtive side effect from chemotherapy and improves the life quality of the patient.

Description

technical field [0001] The present invention relates to a new use of lymphotoxin, in particular to the use of lymphotoxin in the preparation of drugs for increasing the sensitivity of chemotherapeutic drugs. Background technique [0002] Lymphotoxin a (LTα), also known as TNFβ, is a member of the TNF superfamily and an important class of cytokines. LTα is produced by active lymphocytes and is a 25KD secreted glycoprotein. The LT precursor contains 205 amino acid residues, of which 34 amino acid residues encode a signal peptide. The mature LT has 171 amino acid residues (18kD) ( SEQ ID NO: 3), no disulfide bond, position 62 is an N-linked glycosylation site (glycosylation is not necessary for its cytotoxic activity). The N-terminal 1-27 amino acid sequence of LT is a flexible structure, and the deletion of this region does not affect the binding of LT to the receptor and the cytotoxic activity induced by it. [0003] The structure and function of LTα are similar to TNF, and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/19A61K45/06A61P35/00A61P43/00
Inventor 刘彦君沈毅君杨彤王婧吴劲松王征许燕王罗春
Owner 上海复旦张江生物医药股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com